Neurogenic orthostatic hypotension with critical illness neuropathy treated with droxidopa.
نویسندگان
چکیده
☆ Dr. Allen contributed to the drafting and editing; drafting and editing; Dr. Papadopoulos contributed to the contributed to the drafting, editing, and all final decisio interest; Dr. Charles has no conflict of interest; Dr. Pa interest; Dr. Avila has no conflict of interest.Funding: Non ⁎ Corresponding author at: Department of Neurology, M Center, 1275 York Avenue, New York, NY 10065, United S E-mail address: [email protected] (E.K. Avila).
منابع مشابه
Droxidopa and Reduced Falls in a Trial of Parkinson Disease Patients With Neurogenic Orthostatic Hypotension
OBJECTIVES Droxidopa is a prodrug of norepinephrine indicated for the treatment of orthostatic dizziness, lightheadedness, or the "feeling that you are about to black out" in adult patients with symptomatic neurogenic orthostatic hypotension caused by primary autonomic failure including Parkinson disease (PD). The objective of this study was to compare fall rates in PD patients with symptomatic...
متن کاملRandomized Withdrawal Study of Patients With Symptomatic Neurogenic Orthostatic Hypotension Responsive to Droxidopa
UNLABELLED We evaluated whether droxidopa, a prodrug converted to norepinephrine, is beneficial in the treatment of symptomatic neurogenic orthostatic hypotension, which results from failure to generate an appropriate norepinephrine response to postural challenge. Patients with symptomatic neurogenic orthostatic hypotension and Parkinson disease, multiple system atrophy, pure autonomic failure,...
متن کاملDroxidopa for neurogenic orthostatic hypotension
OBJECTIVE To determine whether droxidopa, an oral norepinephrine precursor, improves symptomatic neurogenic orthostatic hypotension (nOH). METHODS Patients with symptomatic nOH due to Parkinson disease, multiple system atrophy, pure autonomic failure, or nondiabetic autonomic neuropathy underwent open-label droxidopa dose optimization (100-600 mg 3 times daily), followed, in responders, by 7-...
متن کاملDroxidopa in patients with neurogenic orthostatic hypotension associated with Parkinson's disease (NOH306A).
BACKGROUND Neurogenic orthostatic hypotension (nOH) is common in Parkinson's disease (PD), and represents a failure to generate norepinephrine responses appropriate for postural change. Droxidopa (L-threo-3,4-dihydroxyphenylserine) is an oral norepinephrine prodrug. OBJECTIVE Interim analyses of the initial patients enrolled in a multicenter, randomized, double-blind, placebo-controlled phase...
متن کاملAnalysis of number needed to treat for droxidopa in patients with symptomatic neurogenic orthostatic hypotension
BACKGROUND Droxidopa is an orally active prodrug that significantly improved dizziness/lightheadedness measured using the Orthostatic Hypotension Symptom Assessment (OHSA) Item 1 in patients with neurogenic orthostatic hypotension (nOH) caused by primary autonomic failure (Parkinson disease, multiple system atrophy, and pure autonomic failure), dopamine β-hydroxylase deficiency, or nondiabetic ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Autonomic neuroscience : basic & clinical
دوره 198 شماره
صفحات -
تاریخ انتشار 2016